Subsequent Events

12 Months Ended

Dec. 31, 2015

Subsequent Events [Abstract]

Subsequent Events

Subsequent Event

TriVascular Merger

On October 26, 2015, the Company entered into an agreement and plan of merger (the “Merger Agreement”), with TriVascular Technologies, Inc. (“TriVascular”) under which the Company agreed to acquire all of TriVascular’s outstanding capital stock through a merger of a direct wholly-owned subsidiary of the Company (“Merger Sub”) with and into TriVascular (the “TriVascular Merger”). On February 3, 2016, the Company completed the acquisition of TriVascular pursuant to the Merger Agreement. Pursuant to the terms of the Merger Agreement, the Company acquired TriVascular through the merger of Merger Sub with and into TriVascular (the “Merger”), with TriVascular surviving the Merger as a wholly-owned subsidiary of Endologix.

Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of capital stock of TriVascular (other than shares for which appraisal rights under Delaware law were properly exercised and other than shares held in treasury by TriVascular or shares held by the Company, any subsidiary of the Company, TriVascular or any subsidiary of TriVascular) was converted into the right to receive (i) $0.34 in cash and (ii) 0.631 shares of Endologix common stock (the “Merger Consideration”). The Company paid approximately $106.8 million in aggregate consideration, consisting of (i) approximately $7.4 million in cash and (ii) approximately $99.4 million worth of 13.6 million shares of the Company’s common stock. The acquisition will be accounted for using the acquisition method; however the accounting was incomplete at the time these financial statements were issued. As a result, the purchase price allocation and pro-forma income statement disclosures have not been provided.